OTCMKTS:GNBT Generex Biotechnology (GNBT) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Generex Biotechnology Stock (OTCMKTS:GNBT) Get Generex Biotechnology alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume60,924 shsMarket Capitalization$73 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Generex Biotechnology Corporation is a biotechnology company historically focused on drug-delivery technologies and immunotherapy development. Its principal platform has been RapidMist, a proprietary buccal delivery system designed to administer medicines through the lining of the mouth rather than by injection or conventional oral tablets. The company’s best-known development program was Oral-lyn, an orally administered insulin formulation intended for people with diabetes. Generex has also pursued peptide-based cancer vaccines and other immunotherapies through its Antigen Express subsidiary, including programs based on its Ii-Key technology, which is designed to enhance immune-system recognition of targeted antigens. Generex has operated primarily as a development-stage biotechnology business, with activities focused on advancing and commercializing pharmaceutical products and platform technologies. Publicly available information about its current operations, leadership, commercial products and geographic reach is limited, and the company’s historical programs may not represent active offerings today.AI Generated. May Contain Errors. Read More Receive GNBT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Generex Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GNBT Stock News HeadlinesBloomage BiotechnologyApril 20, 2023 | forbes.comVir Biotechnology, Inc. (VIR) Interactive Stock Chart - Yahoo FinanceMarch 1, 2023 | finance.yahoo.comWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned.October 12 at 1:00 AM | Awesomely (Ad)Generex Creates Own Regulatory RealityFebruary 26, 2023 | thestreet.comGenerex Plans Reverse Stock SplitFebruary 9, 2023 | thestreet.comGenerex Biotechnology JumpsSeptember 18, 2022 | thestreet.comGenerex Biotechnology Corporation Subsidiary, Olaregen Therapeutix Announces its Malaysian ...July 27, 2021 | apnews.comAGenerex Biotechnology Corporation Subsidiary, Olaregen Therapeutix Announces its Malaysian Distribution Partner, Nexgen Medical, has gained approval for the use of Excellagen® Wound Conforming Matrix from The Malaysian Ministry of Health, its country’s equivalent to the U.S. FDAJuly 26, 2021 | finance.yahoo.comSee More Headlines GNBT Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Generex Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Generex Biotechnology investors own include SELLAS Life Sciences Group (SLS), Amgen (AMGN), VBI Vaccines (VBIV), Novavax (NVAX), Inovio Pharmaceuticals (INO). Company Calendar Today10/12/2026Fiscal Year End7/31/2027Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:GNBT CIK1059784 Webwww.generex.com Phone(416) 364-2551Fax64-7547-7104Employees15Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$2.66 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares122,058,000Free Float79,094,000Market Cap$73 thousand OptionableNot Optionable Beta-0.07 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (OTCMKTS:GNBT) was last updated on 1/27/2023 by MarketBeat.com Staff. From Our PartnersA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredMy biggest prediction yet?!James Altucher called Facebook's rise past 100 billion dollars in 2007 and Apple's run to a trillion years lat...Paradigm Press | SponsoredThe AI Stock to Keep an Eye on Before Election Day (See Why)In 2019, Charles Mizrahi named Marvell Technology his top AI pick. It's since climbed 1300 percent. Now he'...Prosperity Research | SponsoredTrump To Relaunch USD?President Trump's summit with Xi Jinping drew headlines for tariffs and trade truces, but the real story may b...Porter & Company | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Generex Biotechnology Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Generex Biotechnology With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
